Response to Comments: MolDX: Minimal Residual Disease Testing for Cancer

This document is a response to public comments on the MolDX Local Coverage Determination L38779 for Minimal Residual Disease testing in cancer and provides administrative dates: comment period 9/24/2020–11/7/2020, notice period starting 11/11/2021, and effective date 12/26/2021. The text provided does not contain clinical coverage, exclusion, or claim documentation criteria; consult LCD L38779 for the detailed coverage criteria, limitations, and claim documentation requirements. Manual review is recommended because the current text contains only administrative/notice information and not the substantive policy rules.

"This document is a response to comments for MolDX Minimal Residual Disease Testing for Cancer LCD L38779; comment period 2020-09-24 to 2020-11-07; notice period begins 2021-11-11; LCD becomes effec..."

Sign up to see full coverage criteria, indications, and limitations.